Cerebrospinal fluid interleukin-6 may be a biomarker for conversion of clinically isolated syndrome to neuromyelitis optica spectrum disorder
- 2 February 2025
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 95, 106313
Abstract
No abstract availableKeywords
Funding Information
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
This publication has 39 references indexed in Scilit:
- Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experienceDrug Discovery Today, 2021
- Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated DisordersJAMA Neurology, 2018
- Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis opticaClinica Chimica Acta, 2017
- Analysis of the treatment of neuromyelitis opticaJournal of the Neurological Sciences, 2015
- Biomarkers for neuromyelitis opticaClinica Chimica Acta, 2015
- Clinically isolated syndromesThe Lancet Neurology, 2012
- Failure of Natalizumab to Prevent Relapses in Neuromyelitis OpticaArchives of Neurology, 2012
- Astrocytes are active players in cerebral innate immunityTrends in Immunology, 2007
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 2004
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 2001